Insmed Incorporated

Insmed Incorporated

INSMNYSE / NASDAQHealthcareLarge cap

$141.33-$3.13 (-2.2%)

Last close · Data as of Nov 20, 2026

Market cap
$22.7B
P/E
-17.8x
Revenue
$606.4M
Net margin
-210.5%
ROCE
-55.4%

-29.2% over the last year

Insmed Incorporated price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+47.7%
3M
+13.0%
6M
+31.0%
1Y
-29.2%
5Y
Hidden
  • This period includes a one-day price step on 28 May 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$3.13 (-2.2%) from $144 to $141 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in INSM, bought on each weekday since 2021.

News & filings

What Insmed Incorporated filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.3 billion US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.04.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Read moreShow less

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Sector
Healthcare
Shares outstanding
214.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$22.7B
P/E
-17.8x
P/B
30.8x
EV / Sales
36.7x
P/S
37.5x
52-week high
$211.41
52-week low
$91.88

Profitability

Operating margin
-164.0%
Net margin
-210.5%
EBITDA margin
-194.2%
ROE
-172.8%
ROCE
-55.4%
ROA
-56.4%
Asset turnover
0.27

Growth

Revenue
$606.4M
Revenue growth, 1Y
66.7%
Revenue CAGR, 3Y
35.2%
Net profit growth, 1Y
39.7%
Free cash flow
-$967.6M

Solvency

Current ratio
3.83
Debt / Equity
0.04
Debt / Assets
0.01
CFO / Net profit
0.73
Cash / Market cap
2.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$606.4M
Cost of revenue$122.9M
Gross profit$483.5M
Operating expenses$1.5B
Research and development$771.1M
Selling, general and administrative$701.2M
Operating income-$994.8M
Interest and other-$277.0M
Pretax income-$1.3B
Tax and other$5.0M
Net income-$1.3B

Revenue and net profit

Revenue grew 66.7% in FY2025; net profit is the dashed line.

Insmed Incorporated revenue and net profit by fiscal year
Insmed Incorporated revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$245.4M-$481.5M
FY2023$305.2M-$749.6M
FY2024$363.7M-$913.8M
FY2025$606.4M-$1.3B

Cash flows

FY2025: -$935.0M from operations, -$967.6M free after investment (dashed).

Insmed Incorporated operating and free cash flow by fiscal year
Insmed Incorporated operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$400.4M-$410.3M
FY2023-$536.2M-$549.5M
FY2024-$683.9M-$705.8M
FY2025-$935.0M-$967.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$606.4M+66.7%1Y
EBITDA
-$1.2B
Net profit
-$1.3B
Cash from operations
-$935.0M
Free cash flow
-$967.6M
Revenue CAGR, 3Y
35.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$606.4M-$1.2B-$1.3B-$967.6M-172.8%+66.7%+39.7%

Monthly returns

Month-by-month returns of INSM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.3B
Liabilities$1.5B
Equity$739.0M
Paid-in capital$6.4B
Retained earnings-$5.6B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; INSM highlighted.

P/E against peers

INSM has no positive P/E; the peer median is 24.4x.

Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Insmed IncorporatedINSMthis company$22.7B-17.8x30.8x-172.8%—
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
West Pharmaceutical Services, Inc.WST$22.4B45.4x7.1x15.5%28.4x
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Moderna, Inc.MRNA$20.5B-7.3x2.4x-32.6%-7.5x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Peer median—24.4x2.9x10.5%13.6x

Year-to-date ROI

INSM since 1 January, against earlier years.

Historical volatility

INSM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Insmed Incorporated operating margin by fiscal year
Insmed Incorporated operating margin by fiscal year
DateOperating margin
FY2022-194.9%
FY2023-223.1%
FY2024-216.3%
FY2025-164.0%
LineFY2025
Cost of revenueCost Of Revenue$122.9M
Gross profitGross Profit$483.5M
Operating expensesOperating Expense$1.5B
Research and developmentResearch And Development$771.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$6.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$6.0M
Amortization$6.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$6.0M
Total expensesTotal Expenses$1.6B
Pretax incomePretax Income-$1.3B

Learn while you research

Academy chapters picked for Insmed Incorporated and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing67% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →